Treanda Side Effects Linked to Skin Reactions Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
Use of the relatively new cancer drug Treanda together with allopurinol has been linked to severe cases of Stevens Johnson Syndrome (SJS), known as Toxic Epidermal Necrolysis (TEN), and at least one user has died. The lawyers at Saiontz & Kirk, P.A. are reviewing potential cases for individuals who have developed the serious skin condition which may have been caused by Treanda side effects.
Treanda (bendamustine HCl) is a cancer drug that was approved by the FDA in early 2008. It is used for treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
According to Reuters, the manufacturer of Treanda, Cephalon, Inc., disclosed this week in a filing with the U.S. Securities and Exchange Commission that they are aware of two patients who developed Toxic Epidermal Necrolysis. One of the patients died in December 2008.
Stevens-Johnson Syndrome is a debilitating condition that can be caused as a reaction to several medications, where the skin burns from the inside out, producing symptoms like:
- Rash, Blisters or Red Spots on Skin
- Blisters in the Mouth, Eyes, Ears, Nose or Genital Area
- Swelling of the Eyelids
- Fever or Flu-Like Symptoms
In its more severe form, when the skin lesions or burns cover more than 30% of the body, Stevens Johnson Syndrome is called Toxic Epidermal Necrolysis, and can be fatal.
Cephalon now plans to place information on the medication’s label about the potential risk of Stevens Johnson Syndrome side effects when Treanda is taken together with allopurinol, which is often prescribed at the same time to lower uric acid levels.
TREANDA STEVENS-JOHNSON SYNDROME LAWSUITS
The potential for Treanda lawsuits is being evaluated on behalf of individuals diagnosed with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis after taking the cancer drug. If you, a friend or family member may have suffered from the severe skin problems caused by Treanda, request a free consultation and claim evaluation.
